Effects of COVID ‐19 on Parkinson's Disease Clinical Features: A Community‐Based Case‐Control Study-Reference-Cited by-同舟云学术

Effects of COVID ‐19 on Parkinson's Disease Clinical Features: A Community‐Based Case‐Control Study

Published:2020-06-11 Issue:8 Volume:35 Page:1287-1292
ISSN:0885-3185
Container-title:Movement Disorders
language:en
Short-container-title:Mov Disord

Author:

Cilia Roberto¹^ORCID,Bonvegna Salvatore¹,Straccia Giulia¹²,Andreasi Nico Golfrè¹,Elia Antonio E.¹,Romito Luigi M.¹^ORCID,Devigili Grazia¹,Cereda Emanuele³^ORCID,Eleopra Roberto¹

Affiliation:

1. Fondazione IRCCS Istituto Neurologico Carlo Besta, Department of Clinical Neurosciences Parkinson and Movement Disorders Unit Milan Italy

2. Department of Medical Sciences and Advanced Surgery University of Campania Naples Italy

3. Clinical Nutrition and Dietetics Unit Fondazione IRCCS Policlinico San Matteo Pavia Italy

Publisher

Wiley

Subject

Clinical Neurology,Neurology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/mds.28170

Reference31 articles.

1. Coronavirus COVID‐19 global cases by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins.https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6. Accessed May 7 2020.

2. Movement Disorders in the World of COVID ‐19

3. Impact of the COVID ‐19 Pandemic on Parkinson's Disease and Movement Disorders

4. The Impact of the COVID-19 Pandemic on Parkinson’s Disease: Hidden Sorrows and Emerging Opportunities

5. Dopamine-Angiotensin interactions in the basal ganglia and their relevance for Parkinson's disease

Cited by 144 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Parkinson’s Disease and Photobiomodulation: Potential for Treatment;Journal of Personalized Medicine;2024-01-19

2. Extracellular Vesicles: The Invisible Heroes and Villains of COVID‐19 Central Neuropathology;Advanced Science;2023-12-24

3. Occupational performance and participation in children with developmental coordination disorders before and during Covid‐19;Child: Care, Health and Development;2023-12-15

4. Metabolic and toxicological considerations regarding CGRP mAbs and CGRP antagonists to treat migraine in COVID-19 patients: a narrative review;Expert Opinion on Drug Metabolism & Toxicology;2023-11-15

5. Does COVID-19 Trigger the Risk for the Development of Parkinson’s Disease? Therapeutic Potential of Vitamin C;Molecular Neurobiology;2023-11-14